Amedeo Smart

Free Medical Literature Service


 

Amedeo

Prostate Cancer

  Free Subscription

12.02.2024

1 AJR Am J Roentgenol
2 BMC Urol
1 Br J Cancer
1 Cancer
2 Cancer Imaging
1 Clin Med Insights Oncol
1 Eur Radiol
1 Int J Urol
3 J Nucl Med
3 J Urol
1 PLoS One
3 Prostate
1 Urol Int



    AJR Am J Roentgenol

  1. LAWRENCE EM
    Editorial Comment: Similar Upgrade and Downgrade Rates Between PI-RADS Version 2.0 and Version 2.1.
    AJR Am J Roentgenol. 2024;222:e2330325.
    >> Share


    BMC Urol

  2. ZHOU C, Zhang X, Ma H, Zhou Y, et al
    USP54 is a potential therapeutic target in castration-resistant prostate cancer.
    BMC Urol. 2024;24:32.
    >> Share

  3. WINDISCH P, Becker I, Tang H, Schroder C, et al
    Converting between the International Prostate Symptom Score (IPSS) and the Expanded Prostate Cancer Index Composite (EPIC) urinary subscales: modeling and external validation.
    BMC Urol. 2024;24:28.
    >> Share


    Br J Cancer

  4. O'MALLEY DE, Raspin K, Melton PE, Burdon KP, et al
    Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
    Br J Cancer. 2024;130:347-357.
    >> Share


    Cancer

  5. RUAN Y, Heer E, Warkentin MT, Jarada TN, et al
    The association between neighborhood-level income and cancer stage at diagnosis and survival in Alberta.
    Cancer. 2024;130:563-575.
    >> Share


    Cancer Imaging

  6. HU C, Qiao X, Hu C, Cao C, et al
    The practical clinical role of machine learning models with different algorithms in predicting prostate cancer local recurrence after radical prostatectomy.
    Cancer Imaging. 2024;24:23.
    >> Share

  7. GUERRA A, Orton MR, Wang H, Konidari M, et al
    Clinical application of machine learning models in patients with prostate cancer before prostatectomy.
    Cancer Imaging. 2024;24:24.
    >> Share


    Clin Med Insights Oncol

  8. BENJAMIN DJ, Rezazadeh Kalebasty A
    Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022.
    Clin Med Insights Oncol. 2024;18:11795549241227413.
    >> Share


    Eur Radiol

  9. PADHANI AR, Godtman RA, Schoots IG
    Key learning on the promise and limitations of MRI in prostate cancer screening.
    Eur Radiol. 2024 Feb 5. doi: 10.1007/s00330-024-10626.
    >> Share


    Int J Urol

  10. HIYAMA Y
    Editorial Comment: Proctoscopy following transrectal prostate biopsy can control rectal bleeding after prostate biopsy.
    Int J Urol. 2024;31:143.
    >> Share


    J Nucl Med

  11. KUMAR S, Crumbaker M, Emmett L
    Reply: Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:333-334.
    >> Share

  12. RAHBAR K, Boegemann M
    The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
    J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
    >> Share

  13. ASKARI E, Harsini S
    Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:332-333.
    >> Share


    J Urol

  14. MANNAS MP, Deng FM, Ion-Margineanu A, Jones D, et al
    Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies.
    J Urol. 2024;211:384-391.
    >> Share

  15. FLORES JM, Vertosick E, Jenkins LC, Cooper J, et al
    Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
    J Urol. 2024;211:400-406.
    >> Share

  16. LOEB S, Sanchez Nolasco T, Byrne N, Allen L, et al
    Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer.
    J Urol. 2024;211:376-383.
    >> Share


    PLoS One

  17. WU H, Wu Y, He P, Liang J, et al
    A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer.
    PLoS One. 2024;19:e0285745.
    >> Share


    Prostate

  18. ULYS A, Jankevicus F, Jievaltas M, Venckus R, et al
    Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.
    Prostate. 2024 Feb 4. doi: 10.1002/pros.24674.
    >> Share

  19. HOYOS JA, Londono DR, Hoyos AG, Reyes EC, et al
    Impact of presentation timing in metastatic hormone-sensitive prostate cancer: Characterization of patients and identification of prognostic factors.
    Prostate. 2024 Feb 4. doi: 10.1002/pros.24672.
    >> Share

  20. LUO LS, Huang J, Luan HH, Mubarik S, et al
    Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990-2019: A comparable study of key nations with emerging economies.
    Prostate. 2024 Feb 8. doi: 10.1002/pros.24673.
    >> Share


    Urol Int

  21. WU S, Feldman AS, Lin SX, Kim MM, et al
    Estimated Prostate Volume by Semiautomatic Segmentation of MRI Is More Accurately Correlated with Radical Prostatectomy Specimen Weight than the Volume Calculated by Ellipsoid Formula.
    Urol Int. 2024;108:35-41.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016